Timolol eye drops 5mg/ml 5ml №1

NameTimolol sol. The main active ingredient Timolol Release form Eye drops Dosage 2.5 mg / ml Pharmacological action Timolol is a non-selective blocker of beta-adrenergic receptors. It does not have intrinsic sympathomimetic and membrane stabilizing activity. When applied topically in the form of eye drops, timolol reduces both normal and elevated intraocular pressure by reducing the formation of intraocular fluid. Does not affect pupil size and accommodation. When applied topically, timolol maleate quickly penetrates the cornea. After instillation of eye drops, the maximum concentration of timolol in the aqueous humor of the eye is observed after 1-2 hours. Indications for use Chronic open-angle glaucoma; secondary glaucoma (uveal, aphakic, post-traumatic); acute increase in ophthalmotonus; as an additional tool used to reduce intraocular pressure in angle-closure glaucoma (in combination with miotics). Dosage and administration The drug is used as instillations into the lower conjunctival sac of the affected eye. Treatment begins with a 0.25% solution (1 drop 1-2 times / day), with insufficient effectiveness, a 0.5% solution is used (1 drop 1-2 times / day). If intraocular pressure normalizes with regular use, the dosage should be limited to 1 time per day, 1 drop in the morning. Treatment is carried out, as a rule, for a long time. The duration of the course of treatment depends on the course of the disease and is determined by the doctor. A break in the use of the drug or a change in dosage is carried out only as prescribed by the attending physician. Nasolacrimal duct occlusion or eyelid closure for 2 minutes is recommended to limit systemic drug absorption. As a result, the risk of developing systemic adverse reactions is reduced and local activity is increased. Recommendations for the use of vials with dropper caps: before using the drug, remove the aluminum cap from the vial, remove the rubber stopper and close the vial with a dropper cap, previously released from the packaging. Then remove the cap from the dropper cap, turn the vial over, drip the required number of drops of the drug. After use, return the bottle to a vertical position and put the cap on the dropper cap. Recommendations for the use of dropper tubes: before using the drug, remove the protective cap from the dropper tube, cut off the membrane of the body neck with scissors without damaging the threaded part. Turn the body of the tube-dropper with the drug neck down and gently press the body of the tube-dropper, using it as a pipette. After using the dose recommended by the doctor or indicated in the instructions for use of the medicinal product, turn the body of the dropper tube with the threaded part up and screw on the protective cap. Use during pregnancy and lactation Pregnancy There are insufficient data on the use of timolol in pregnant women. Should not be used during pregnancy unless absolutely necessary. To reduce the systemic effect, see the section “Method of application and dosing regimen”. Epidemiological studies have not revealed the effect of beta-blockers on the development of congenital malformations in the fetus (teratogenic effect), but have shown intrauterine growth retardation when administered orally. Signs and symptoms of beta-blockade (bradycardia, hypotension, respiratory distress syndrome, hypoglycemia) have been observed in newborns if beta-blockers were used before delivery. It is necessary to carefully monitor newborns during the first days of life if Timolol was used before delivery. Lactation Beta-blockers are excreted in breast milk. However, it is unlikely that timolol will be present in breast milk in sufficient quantities to cause the development of clinical symptoms of beta-blockade in newborns. Reducing systemic absorption, see section “Method of application and dosing regimen”. Influence on the ability to drive vehicles and other potentially dangerous mechanisms During treatment, visual disturbances, dizziness, fatigue, lowering blood pressure are possible, care must be taken when driving vehicles and engaging in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions. After using the drug, temporary visual disturbances are possible, it is not recommended to drive vehicles and work with moving mechanisms until vision is restored. Precautions Like other topical drugs, ophthalmic drops containing timolol are absorbed systemically. Topical beta-blockers cause the development of undesirable adverse reactions from the cardiovascular, pulmonary and other systems, as with the systemic use of beta-blockers. The incidence of systemic adverse reactions after the use of eye drops is lower than with the systemic use of beta-blockers. Reducing systemic absorption, see section “Method of application and dosing regimen”. Cardiac disease In patients with cardiovascular disease (eg, ischemic heart disease, Prinzmetal’s angina, heart failure) and low blood pressure, the need for beta-blockers should be carefully considered and alternative drugs should be considered. Stimulation of the sympathetic system may be necessary to maintain blood flow in patients with impaired myocardial contractility, and its inhibition may cause decompensation of heart failure. Patients with cardiovascular disease should be monitored for worsening symptoms of these diseases and adverse reactions. Because of their negative effect on the timing of arousal, beta-blockers should be used with caution in patients with first-degree heart block. Vascular Diseases Patients with peripheral circulatory disorders/diseases (severe Raynaud’s disease or Raynaud’s syndrome) should be treated with caution. Respiratory impairment There have been reports of respiratory reactions, including death due to bronchospasm, in patients with bronchial asthma when using eye drops containing beta-blockers. Timolol should be used with caution in patients with mild to moderate chronic obstructive pulmonary disease and only if the potential benefit outweighs the risk. Hypoglycemia/Diabetes Beta-blockers should be used with caution in patients susceptible to spontaneous hypoglycemia or in patients with unstable diabetes, as beta-blockers may mask the signs and symptoms of acute hypoglycemia. Beta-blockers may mask the symptoms of hyperthyroidism. Corneal disorders Ophthalmic beta-blockers can cause dry eyes. Patients with corneal disease should be treated with caution. Other beta-blockers The effect on intraocular pressure or the known systemic effect of beta-blockers may be potentiated when the patient is already on systemic beta-blockers. The response to these drugs must be carefully monitored. The use of two beta-blockers for topical use is not recommended (see section “Interaction with other drugs”). Anaphylactic Reactions When taking topical beta-blockers, patients with a history of atopic or severe anaphylactic reactions to various allergens may be more reactive to repeated allergen administration and not respond to the usual dose of epinephrine in the treatment of an anaphylactic reaction. Detachment of the choroid of the eye There are cases of detachment of the choroid of the eye when using drugs that prevent the formation of intraocular fluid (for example, timolol, acetazolamide) after filtering operations. Anesthesia, Surgical Ophthalmic beta-blockers can block the systemic action of beta-agonists such as adrenaline. The anesthesiologist should be informed if the patient is receiving timolol. When using timolol, it is necessary to control the function of lacrimation, the integrity of the cornea and the field of vision, it is necessary to control intraocular pressure (3-4 weeks after the start of therapy). Timolol contains the preservative benzalkonium chloride, which can cause eye irritation, be absorbed by soft contact lenses, causing discoloration and adverse effects on eye tissue. Contact lenses should be removed before using the drug and, if necessary, put them back on no earlier than 15 minutes after instillation. When transferring patients to treatment with timolol, it may be necessary to correct refractive changes caused by previously used miotics. Application in pediatrics. Data on the efficacy and safety of the drug Timolol in children under 18 years of age are not available. Interaction with other drugs Special studies on the study of interaction with other drugs have not been conducted. There may be an additional effect leading to hypotension and/or severe bradycardia when a topical beta-blocker solution is used in conjunction with oral forms of calcium channel blockers (calcium ion antagonists), beta-adrenergic blockers, antiarrhythmic drugs (including amiodarone), digitalis glycosides , parasympathomimetics, guanethidine. There have been reports of an increased risk of systemic adverse reactions (decrease in heart rate, depression) while using timolol with P450 CYP2D6 inhibitors (eg, quinidine, fluoxetine, paroxetine). There have been reports of the development of mydriasis (dilated pupils) with the combined use of adrenaline (epinephrine) and eye drops containing beta-blockers. Contraindications Hypersensitivity to the active or excipient. Reactive airway disease or bronchial asthma, history of severe chronic obstructive airway disease. Sinus bradycardia, sick sinus syndrome, sinoatrial block, second or third degree atrioventricular block not controlled by a pacemaker. Severe heart failure, cardiogenic shock. Allergic reactions with generalized skin rashes, severe atrophic rhinitis, degenerative diseases of the cornea. Children’s age up to 18 years. Composition active substance: timolol (in the form of timolol maleate) – 5.0 mg / ml; excipients: disodium phosphate dihydrate, sodium dihydrogen phosphate dihydrate, sodium chloride, disodium edetate, benzalkonium chloride, water for injection. Overdose It is possible to develop systemic effects characteristic of beta-blockers: dizziness, headache, arrhythmia, bradycardia, bronchospasm, nausea, vomiting. Treatment: immediately rinse eyes with water or saline, symptomatic therapy. Side effects When applied topically, ophthalmic beta-blockers are absorbed into the bloodstream, which can lead to the development of undesirable side reactions, such as systemic use. The risk of developing systemic adverse reactions with topical application is lower than with systemic use. The following adverse reactions reflect the class effect characteristic of the entire group of topical beta-blockers. From the immune system: systemic allergic reactions, including Quincke’s edema, urticaria, localized and generalized rash, itching, anaphylactic reactions. On the part of metabolism: hypoglycemia. On the part of the psyche: insomnia, depression, nightmares, memory loss. From the nervous system: fainting, cerebrovascular complications, cerebral ischemia, increased manifestation of signs and symptoms of myasthenia gravis (asthenic bulbar palsy), dizziness, paresthesia, headache. On the part of the organs of vision: signs and symptoms of eye irritation (burning, stinging, itching, tearing, redness), blepharitis, keratitis, decreased visual acuity and detachment of the choroid after filtration surgery (see section “Precautions”), decreased sensitivity of the cornea , dry eye, corneal erosion, ptosis, diplopia. From the side of the cardiovascular system: bradycardia, chest pain, palpitations, edema, arrhythmias, congestive heart failure, atrioventricular blockade, cardiac arrest, heart failure, hypotension, Raynaud’s syndrome, cold hands and feet. From the respiratory system: bronchospasm (mainly in patients with a history of bronchospastic disease), shortness of breath, cough. From the digestive system: taste perversion, nausea, dyspepsia, diarrhea, dry mouth, abdominal pain, vomiting. On the part of the skin and subcutaneous tissue: alopecia, psoriasis-like rash, exacerbation of psoriasis, skin rash. From the musculoskeletal system: myalgia. From the reproductive system: sexual dysfunction, decreased libido. Other: asthenia/weakness. In case of adverse reactions, including those not listed in this leaflet, you should consult a doctor. Storage conditions In a place protected from light at a temperature not exceeding 25 ° C. Store the opened dropper tube in a place protected from light at a temperature of 15 ° C to 25 ° C for 2 weeks. Keep out of the reach of children. Buy Timolol eye drops 5mg/ml 5ml №1 Price for Timolol eye drops 5mg/ml 5ml №1